Table 2.
The Notable Adverse Events (AEs) in the Two Time of CAR-T Cell Therapies
| Events | CD19 CAR-T Therapy | CD22 CAR-T Therapy | ||
|---|---|---|---|---|
| DLBCL | ALL | DLBCL | ALL | |
| General condition | ||||
| Temperature ≥38 °C (fever) | 7/7 (100%) | 6/6 (100%) | 1/7 (14.29%) | 4/6 (66.67%) |
| Chills | 2/7 (28.57%) | 4/6 (66.67%) | 0/7 (0%) | 1/6 (16.67%) |
| Fatigue | 4/7 (57.14%) | 5/6 (83.33%) | 3/7 (42.86%) | 4/6 (66.67%) |
| Headache | 0/7 (0%) | 3/6 (50%) | 0/7 (0%) | 0/6 (0%) |
| Muscular weakness | 1/7 (14.29%) | 4/6 (66.67%) | 0/7 (0%) | 1/6 (16.67%) |
| Organ toxicities | ||||
| Hematological | ||||
| Neutropenia (grade 3/4) (<1*10^9/L) | 3/7 (42.86%) | 6/6 (100%) | 1/7 (14.29%) | 2/6 (33.33%) |
| Anemia (grade 3/4) (<80g/L) | 2/7 (28.57%) | 5/6 (83.33%) | 1/7 (14.29%) | 3/6 (50%) |
| Thrombocytopenia (grade 3/4) (<50*10^9/L) | 2/7 (28.57%) | 6/6 (100%) | 1/7 (14.29%) | 5/6 (83.33%) |
| Respiratory | ||||
| Hypoxia (SaO2 <90%) | 1/7 (14.29%) | 2/6 (33.33%) | 0/7 (0%) | 0/6 (0%) |
| Dyspnoea | 0/7 (0%) | 4/6 (66.67%) | 0/7 (0%) | 0/6 (0%) |
| Cough | 2/7 (28.57%) | 3/6 (50%) | 0/7 (0%) | 1/6 (16.67%) |
| Pleural effusion | 2/7 (28.57%) | 3/6 (50%) | 0/7 (0%) | 2/6 (33.33%) |
| Gastrointestinal | ||||
| Nausea | 3/7 (42.86%) | 4/6 (66.67%) | 1/7 (14.29%) | 1/6 (16.67%) |
| Vomiting | 1/7 (14.29%) | 2/6 (33.33%) | 0/7 (0%) | 0/6 (0%) |
| Decreased appetite | 1/7 (14.29%) | 3/6 (50%) | 0/7 (0%) | 1/6 (16.67%) |
| Hepatic | ||||
| Increased serum ALT, AST | 2/7 (28.57%) | 4/6 (66.67%) | 1/7 (14.29%) | 2/6 (33.33%) |
| Increased serum bilirubin levels | 1/7 (14.29%) | 2/6 (33.33%) | 0/7 (0%) | 0/6 (0%) |
| Renal | ||||
| Increased serum creatinine levels | 0/7 (0%) | 3/6 (50%) | 0/7 (0%) | 1/6 (16.67%) |
| Oliguria | 2/7 (28.57%) | 3/6 (50%) | 1/7 (14.29%) | 1/6 (16.67%) |
| Heart | ||||
| Tachycardia | 2/7 (28.57%) | 4/6 (66.67%) | 0/7 (0%) | 2/6 (33.33%) |
| Arrhythmia | 0/7 (0%) | 3/6 (50%) | 0/7 (0%) | 0/6 (0%) |
| Systolic blood pressure <90 mm Hg | 0/7 (0%) | 2/6 (33.33%) | 0/7 (0%) | 0/6 (0%) |
| Coagulopathy | ||||
| Disseminated intravascular coagulation | 0/7 (0%) | 1/6 (16.67%) | 0/7 (0%) | 0/6 (0%) |
| Neurological | ||||
| Encephalopathy | 0/7 (0%) | 0/6 (0%) | 0/7 (0%) | 0/6 (0%) |
| Confused state | 0/7 (0%) | 0/6 (0%) | 0/7 (0%) | 0/6 (0%) |
| Dizziness | 0/7 (0%) | 4/6 (66.67%) | 0/7 (0%) | 1/6 (16.67%) |
| Aphasia | 0/7 (0%) | 0/6 (0%) | 0/7 (0%) | 0/6 (0%) |
| Somnolence | 1/7 (14.29%) | 3/6 (50%) | 0/7 (0%) | 2/6 (33.33%) |
| Cytokine release syndrome (CRS) | ||||
| Grade 0 CRS | 5/7 (71.43%) | 0/6 (0%) | 4/7 (57.14%) | 0/6 (0%) |
| Grade 1 CRS | 1/7 (14.29%) | 0/6 (0%) | 2/7 (28.57%) | 3/6 (50%) |
| Grade 2CRS | 1/7 (14.29%) | 2/6 (33.33%) | 1/7 (14.29%) | 2/6 (33.33%) |
| Grade 3 CRS | 0/7 (0%) | 2/6 (33.33%) | 0/7 (0%) | 1/6 (16.67%) |
| Grade 4 CRS | 0/7 (0%) | 2/6 (33.33%) | 0/7 (0%) | 0/6 (0%) |
| Grade 5 CRS | 0/7 (0%) | 0/6 (0%) | 0/7 (0%) | 0/6 (0%) |
| Immune effector cell associated neurotoxic syndrome (ICANS) | ||||
| Grade 1 ICANS | 0/7 (0%) | 1/6 (16.67%) | 0/7 (0%) | 0/6 (0%) |
| Grade 2 ICANS | 0/7 (0%) | 1/6 (16.67%) | 0/7 (0%) | 0/6 (0%) |
| Grade 3 ICANS | 0/7 (0%) | 0/6 (0%) | 0/7 (0%) | 0/6 (0%) |
| Grade 4 ICANS | 0/7 (0%) | 0/6 (0%) | 0/7 (0%) | 0/6 (0%) |
| Grade 5 ICANS | 0/7 (0%) | 0/6 (0%) | 0/7 (0%) | 0/6 (0%) |